TY - JOUR
T1 - Weight gain associated with integrase stand transfer inhibitor use in women
AU - Kerchberger, Anne Marie
AU - Sheth, Anandi N.
AU - Angert, Christine D.
AU - Mehta, C. Christina
AU - Summers, Nathan A.
AU - Ofotokun, Ighovwerha
AU - Gustafson, Deborah
AU - Weiser, Sheri D.
AU - Sharma, Anjali
AU - Adimora, Adaora A.
AU - French, Audrey L.
AU - Augenbraun, Michael
AU - Cocohoba, Jennifer
AU - Kassaye, Seble
AU - Bolivar, Hector
AU - Govindarajulu, Usha
AU - Konkle-Parker, Deborah
AU - Golub, Elizabeth T.
AU - Lahiri, Cecile D.
N1 - Publisher Copyright:
© The Author(s) 2019.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Background. Integrase strand-transfer inhibitor (INSTI)-based antiretroviral therapy (ART) is recommended for human immunodeficiency virus (HIV) management. Although studies have suggested associations between INSTIs and weight gain, women living with HIV (WLHIV) have been underrepresented in research. We evaluated the effect of switching or adding INSTIs among WLHIV. Methods. Women enrolled in the Women's Interagency HIV Study (WIHS) from 2006-2017 who switched to or added an INSTI to ART (SWAD group) were compared to women on non-INSTI ART (STAY group). Body weight, body mass index (BMI), percentage body fat (PBF), and waist, hip, arm, and thigh circumferences were measured 6-12 months before and 6-18 months after the INSTI switch/add in SWAD participants, with comparable measurement time points in STAY participants. Linear regression models compared changes over time by SWAD/STAY group, adjusted for age, race, WIHS site, education, income, smoking status, and baseline ART regimen. Results. We followed 1118 women (234 SWAD and 884 STAY) for a mean of 2.0 years (+/- 0.1 standard deviation [SD]; mean age 48.8 years, SD +/- 8.8); 61% were Black. On average, compared to the STAY group, the SWAD group experienced mean greater increases of 2.1 kg in body weight, 0.8 kg/m2 in BMI, 1.4% in PBF, and 2.0, 1.9, 0.6, and 1.0 cm in waist, hip, arm, and thigh circumference, respectively (all P values < .05). No differences in magnitudes of these changes were observed by INSTI type. Conclusions. In WLHIV, a switch to INSTI was associated with significant increases in body weight, body circumferences, and fat percentages, compared to non-INSTI ART. The metabolic and other health effects of these changes deserve further investigation.
AB - Background. Integrase strand-transfer inhibitor (INSTI)-based antiretroviral therapy (ART) is recommended for human immunodeficiency virus (HIV) management. Although studies have suggested associations between INSTIs and weight gain, women living with HIV (WLHIV) have been underrepresented in research. We evaluated the effect of switching or adding INSTIs among WLHIV. Methods. Women enrolled in the Women's Interagency HIV Study (WIHS) from 2006-2017 who switched to or added an INSTI to ART (SWAD group) were compared to women on non-INSTI ART (STAY group). Body weight, body mass index (BMI), percentage body fat (PBF), and waist, hip, arm, and thigh circumferences were measured 6-12 months before and 6-18 months after the INSTI switch/add in SWAD participants, with comparable measurement time points in STAY participants. Linear regression models compared changes over time by SWAD/STAY group, adjusted for age, race, WIHS site, education, income, smoking status, and baseline ART regimen. Results. We followed 1118 women (234 SWAD and 884 STAY) for a mean of 2.0 years (+/- 0.1 standard deviation [SD]; mean age 48.8 years, SD +/- 8.8); 61% were Black. On average, compared to the STAY group, the SWAD group experienced mean greater increases of 2.1 kg in body weight, 0.8 kg/m2 in BMI, 1.4% in PBF, and 2.0, 1.9, 0.6, and 1.0 cm in waist, hip, arm, and thigh circumference, respectively (all P values < .05). No differences in magnitudes of these changes were observed by INSTI type. Conclusions. In WLHIV, a switch to INSTI was associated with significant increases in body weight, body circumferences, and fat percentages, compared to non-INSTI ART. The metabolic and other health effects of these changes deserve further investigation.
KW - HIV positive
KW - Integrase strand transfer inhibitors
KW - Weight gain
KW - Women
UR - http://www.scopus.com/inward/record.url?scp=85088849479&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088849479&partnerID=8YFLogxK
U2 - 10.1093/cid/ciz853
DO - 10.1093/cid/ciz853
M3 - Article
C2 - 31504324
AN - SCOPUS:85088849479
SN - 1058-4838
VL - 71
SP - 593
EP - 600
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 3
ER -